Revenue up 21.9% but FY24 loss widened to $29.5m with cash runway thinning

What changed

Operating revenue rose 21.9% to $23.9m (FY23: $19.6m), supported by an 18% lift in US average sales price per Cxbladder test in 2H24 and a 2% rise in commercial US test volumes. Despite that, the pre-tax and after-tax loss both widened 9.5% to $29.5m; with nil tax in both periods, PBT and NPAT move identically. Operating cash outflow was broadly flat at $25.8m (FY23: $25.6m). Cash on hand fell to $29.3m from $33.2m, total equity contracted 34% to $54.6m, and total assets dropped 28% to $65.4m. Gross borrowings remain negligible at $0.3m, so the group is still in a net cash position of roughly $29.0m. The Commercial segment drove essentially all disclosed operating revenue but still posted a segment result of -$17.3m, close to FY23's -$17.1m.

What matters

• Growth is not yet converting to lower burn. Revenue grew $4.3m but the loss widened $2.6m and operating cash outflow was essentially unchanged. The ASP improvement and reduced sales-team headcount have not compressed the cost base meaningfully.
• Cash runway is the central issue. Pre-lease free cash flow was -$27.1m (FY23: -$28.5m). Against $29.3m of closing cash, that leaves roughly a year of operating headroom at the current pace before any further funding, cost action or revenue step-up.
• Balance-sheet erosion is visible. Equity fell $28.1m, broadly matching the NPAT loss, while liabilities rose 32.8% to $10.8m. Return on equity weakened to -54.1% from -32.6%.

Expectations

No formal revenue or earnings targets, and no forward-work disclosure, are provided in the supplied material. The shape data show HY24 delivered 54.8% of FY24 operating revenue and 51.6% of FY24 NPAT, implying a slightly first-half-weighted year; the implied 2H24 revenue of $10.8m is lower than the $13.1m HY24 print. That cuts against a simple "momentum into FY25" read and the release does not quantify any FY25 guideposts. Management references a cash runway to a future date, but the specific endpoint is not captured in the excerpts supplied.

Quality of result

The revenue uplift looks genuine: ASP is up meaningfully and capex fell from $2.9m to $1.4m (5.7% of revenue versus 14.8%), lowering reported investment intensity. However, durability is limited. Operating cash outflow tracked the reported loss almost one-for-one (FCF/NPAT of 91.9% versus 105.6%), confirming the loss is cash, not accruals. Working capital was a small drag rather than a tailwind: receivable days improved to 39 from 51.7, but inventory days edged up and operating working capital rose $0.2m. FX also flattered the cash line, with a $0.7m translation gain (FY23: $2.2m). Strip the capex cut and the underlying burn profile has not improved.

Unresolved

• What is the disclosed cash-runway date, and does it assume current revenue run-rate, the 2H24 ASP, or further cost action?
• Why did implied 2H24 revenue ($10.8m) step down from HY24 ($13.1m) despite higher ASP — was it volume, reimbursement timing, or one-off HY items?
• The Research segment reported a -$12.3m result with no separately disclosed FY24 revenue, so the split between commercial grant/other income and loss drivers is unclear.
• With equity down 34% and cash down $4.0m, what capital-raising or cost-reduction optionality has the board flagged beyond attrition in the sales team?

This briefing cannot assess Medicare reimbursement outcomes, detailed segment revenue reconciliation, or management's specific runway date, as those disclosures are not in the supplied extraction data.

Key metrics

Segment breakdown

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.